Lung Cancer (NSCLC) [Plasma]
EGFR and KRAS testing of cfDNA (plasma) for NSCLC. This EQA is sponsored.
Sponsored by
, 
Overview
The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.
At a glance
Product Code:
02-LUNGP-27
Target/Genes:
The scope of this EQA includes testing for actionable and resistant variants in the EGFR and KRAS genes in cfDNA from plasma in Non Small Cell Lung Cancer in the context of Tyrosine Kinase inhibitors and KRAS inhibitors therapies.
Technology:
Any molecular test
Sample Type:
Plasma (cfDNA)
Submit Results In:
English, French, German, Italian, Spanish
Accredited:
Pending
Key Dates
28/02/2027
Sep-27
September - November 2027
May - June 2028
Sample Details
Three mock clinical cases with matching samples will be provided, 3ml artificial / synthetic plasma is provided per case.
Complete information will be available in scheme instructions.
EQA Results
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participation Information
The minimum requirement is EGFR testing. If you provide a clinical service for KRAS and/or BRAF testing, this should be included.
Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.
This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. EMQN would like to acknowledge and thank AstraZeneca for this support.
Limited to 320 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
This EQA is provided in collaboration with GenQA.
Send your enquiry by submitting the form
Closes in 111 days
From £310.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
- Submit results in 5 languages
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.